CDMO Samsung Biologics is preparing to construct a fifth biomanufacturing facility after acquiring 10,000 m2 of land in Songdo, Korea. In 2020, Samsung Biologics laid plans for a fourth ‘super plant’ at its site in Songdo, Incheon at a cost of over 2 trillion Korean won—roughly equivalent to $2 billion. Construction of the facility, which will house 256,000 liters of mammalian production capacity, is underway but in the meantime the contract development and manufacturing organization (CDMO) has made a move…
